Hologic, Inc. $HOLX Shares Purchased by FORA Capital LLC

Key Points

• FORA Capital LLC increased its stake in Hologic, Inc. by 268.5%, now holding 54,598 shares valued at approximately $3.37 million.
• Hologic's recent quarterly earnings showed $1.08 EPS, exceeding analysts' estimates and indicating a revenue increase of 1.2% year-over-year.
• The consensus target price for Hologic shares is $78.00, with a mix of upgrades and ratings from several brokerages.

FORA Capital LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 268.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,598 shares of the medical equipment provider's stock after purchasing an additional 39,780 shares during the quarter. FORA Capital LLC's holdings in Hologic were worth $3,373,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HOLX. Victory Capital Management Inc. increased its stake in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the period. Nuance Investments LLC increased its stake in shares of Hologic by 623.7% during the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after buying an additional 931,920 shares during the period. Redwood Wealth Management Group LLC purchased a new position in shares of Hologic during the first quarter valued at $3,534,000. Invesco Ltd. increased its stake in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after buying an additional 764,573 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Up 0.8%

Shares of HOLX stock traded up $0.50 during trading hours on Friday, reaching $67.12. 1,080,191 shares of the company's stock were exchanged, compared to its average volume of 1,721,362. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The stock has a market cap of $14.93 billion, a PE ratio of 27.85, a PEG ratio of 2.44 and a beta of 0.49. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock's fifty day moving average price is $66.15 and its two-hundred day moving average price is $62.50.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm earned $1.06 earnings per share. The company's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HOLX. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Mizuho set a $75.00 target price on Hologic in a research note on Thursday, July 31st. UBS Group lifted their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Stephens cut their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.